Core Viewpoint - H-shares are outperforming A-shares, with the Hang Seng Index leading in the global capital market since April 2024, experiencing four rounds of technical bull markets, while the pharmaceutical sector leads the market, and technology and discretionary consumption lag behind [1][4]. Group 1: AH Premium Index - The AH premium index fell over 10%, reaching a five-year low of 127.84 points on June 11, down from over 160 points in February 2024 [2]. - The decline in the AH premium index indicates a narrowing discount of H-shares compared to A-shares, attributed to the better performance of H-shares [2]. - The index measures the price differences of A-shares and H-shares of the same companies, reflecting the relative premium or discount [2]. Group 2: IPO Market Performance - The Hong Kong IPO market has seen explosive growth, with 31 new companies listed as of June 10, reclaiming the top position in global IPO fundraising [3]. - The resilience of the Hong Kong market is notable, even in the face of unexpected challenges such as "reciprocal tariffs" [3]. Group 3: Market Dynamics and Investment Trends - The Hang Seng Index has risen over 21% since the low on April 9, entering a technical bull market, with significant sector performance divergence [4]. - The pharmaceutical sector has shown the highest ETF growth at 42.69%, while technology and discretionary consumption sectors lagged behind [4]. - Southbound capital has seen a net inflow of 674.18 billion HKD this year, indicating strong foreign interest in Hong Kong stocks [4]. Group 4: Sector Adjustments and Future Outlook - The recent adjustment in the technology sector is seen as both coincidental and inevitable, with AI-related stocks experiencing a temporary cooling off after a strong previous performance [5]. - The Hong Kong market is becoming a key platform for global capital, with an influx of leading companies and a favorable valuation environment attracting foreign investment [5].